A clear opportunity for precision diabetes therapy in monogenic IR is offered by the IR and lipodystrophy caused by mutations in PPARG, which encodes the target for thiazolidinediones (TZDs) such as pioglitazone59,60. Here, PPARG is linked to lipodystrophy.